Noxopharm Ltd has released a press release.
VEYONDA - Registered Trade Mark for NOX66
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Release of DARRT-1 Preliminary Safety Data
- Pre-Clinical data confirms Radio-Enhancing potential
- End-of-Study Clinical Data shows benefit of NOX66
- NOX to present at American Society of Clinical Oncology
- NOX CEO interview on near complete NOX66 chemotherapy trial
Later from Noxopharm
- Nyrada-Key progress with cholesterol-lowering drug candidate
- NOX to support expanded LuPIN study
- NOX Subsidiary Announces Important Drug Discovery
- Change of Registry Address: Automic P/L - Sydney Office
- Appendix 4C - quarterly
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm